ImpediMed (IPD) H2 2024 earnings summary

Executive summary

• FY 2024 global revenue declined 9% year-over-year to $10.3 million, mainly due to the end of AstraZeneca clinical trial revenues, but SOZO Core Business revenue grew 14% to $9.7 million and annual recurring revenue (ARR) increased 18% compared to FY 2023.

• Patient tests rose 18% to 250,000, supporting device renewals and reflecting strong lymphedema prevention program engagement.

• The U.S. market generated 90% of core business revenue, with a strategic focus on expanding payer coverage and accelerating sales in high-reimbursement states.

• New executive and sales leadership drove improved lead generation, higher conversion rates, and a 20% reduction in sales lead time in recent months.

• Operating loss before tax narrowed to $19.8 million from $20.5 million in FY23.

Financial highlights

• SOZO Core Business revenue increased by $1.2 million (14%) year-over-year to $9.7 million.

• ARR increased 18% year-over-year to $11.0 million.

• Gross margin improved to 87.3% from 86.4% in FY 2023.

• Cash balance at June 2024 was AUD 24.6 million, down from $45.7 million in FY23.

• Operating cash outflow was $17.8 million, similar to the prior year.

• Other income rose by $1.2 million, driven by a non-recurring $1.9 million U.S. government grant.

Outlook and guidance

• Targeting free cash flow break-even by July 2025 through sales growth and strict cost management.

• Cash expenditure forecast to be 10% lower in FY 2025, mainly from headcount and salary adjustments, while investing in customer-facing roles.

• Focused on achieving 85% national payer coverage in the U.S. and expanding into new oncology indications.

• Positive sales momentum expected to continue, with 14 conferences scheduled and further pipeline growth anticipated.

• Immediate focus on US BCRL sales execution, lead generation, and conversion in key states.